Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial
-
Published:2023-10
Issue:5
Volume:21
Page:615.e1-615.e8
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Orlando ValentinaORCID, Drubay DamienORCID, Lavaud Pernelle, Faivre Laura, Lesaunier François, Delva Remy, Gravis GwenaëlleORCID, Rolland FrédéricORCID, Priou Frank, Ferrero Jean-Marc, Houede NadineORCID, Mourey Loic, Theodore Christine, Krakowski Ivan, Berdah Jean-François, Baciuchka Marjorie, Laguerre Brigitte, Fléchon Aude, Grosse-Goupil MarineORCID, Cojean-Zelek Isabelle, Oudard Stéphane, Labourey Jean-Luc, Chinet-Charrot Paule, Legouffe Eric, Lagrange Jean-Léon, Linassier Claude, Deplanque Gaël, Beuzeboc Philippe, Davin Jean-Louis, Martin Anne-LaureORCID, Brihoum Meryem, Culine StéphaneORCID, Teuff Gwénaël Le, Fizazi Karim
Funder
Ligue Contre le Cancer UNICANCER
Reference32 articles.
1. Time trends and local variation in primary treatment of localized prostate cancer;Cooperberg;J Clin Oncol,2010 2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA,1998 3. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update;Partin;JAMA,1997 4. A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial;Fizazi;Eur J Cancer,2012 5. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial;Fizazi;Lancet Oncol,2015
|
|